According to their website, only 4 analysts follow NEWM. We need more coverage and upgrades, IMO. This will come as time goes by and NEWM has more history as a company. In the meantime, enjoy the dividend.
My gut tells me that the upcoming results and call will support a higher PPS in the future and bring the dividend yield down to a level closer to its peers. GLTA longs! NEWM doing well!
Established a significant position after the price drop, again, after selling all my shares around $24 range, except for the ones given to me from the spin-off ones. I like the dividend and look forward to a higher PPS as the market catches up. GLTA longs!
You handle says it all. Right on the mark. Kinkaid Institution?........huh.......what is that? Never heard of it. The fourth stooge just appeared. Moe, Larry and Curley and now Dopey. Thanks for the laugh!
Great call! HyQvia doing very well and sold at a 30% premium. Looking to move it from the cost sensitive hospital model to the home administered model. IMO, more importantly, a great ambassador for us to partner with other companies due to its ongoing success in the US.
I'm an investor, not a trader and my time horizon is much longer. The last time I bought was after the SO and have a much lower average price. After the July 9th 8K, I understood the landscape and set my position at that time and only top it off after the SO. We are all waiting for news and expect to have a better idea from the CC. Good luck to you.
This call was a waste, but tomorrow morning there is a Baxalta webcast at 7:30 AM CDT or 8:30 AM in New York.
I agree with your assessment, but I think that a deal can still be struck before any work on patents filing, etc. takes place. It's all how a contract is worded that counts. I think that Riley was aware of all of the possibilities before he said that a deal would take place by end of Q2. While, the timing will be off, I don't think we are talking months. Total conjecture on my part, but that is what my gut tells me. We'll see. Thanks.
All the work relating to the possible partnering is not being held up by the article not being published. I think it would be great if the article and PR came out soon for validation purposes, but any deals that are being worked out are not being held up. Without saying what the results of the study are, Riley can still carefully tell us what the plan is on August 10th. Any deep probing question by analysts can be met with, "I am sorry, as I mentioned earlier, I cannot answer any question as it relates to the study results. All I can say is we are currently sharing data with potential partners and if we cannot come up with an agreement that is beneficial to SYN, we are prepared to go forward alone."
As you can see, this is an out of control board. Like I said, only Rocketjock1 posts are worth reading. The others are mostly manipulative posts by longs and shorts. The value in the shares is mostly in the potential on the Phase 3 NeuVax trial. IMO, GALE made a wrong turn by getting into the resale business due to the cash drain and distraction, first with Abstral and now, Zuplenz. The shareholder lawsuits have also been a cash drain and a distraction for all. GALE is also involved in an SEC inquiry due to a stock promoter firm, "The Dream Team" that is alleged pumped up the stock while board members, Ahn exercised their stock options at the height, or near the height of the PPS at the time. Now the PPS is is a fraction of what it was. Most think, that the SEC inquiry is over and that GALE was not the party being investigated. I would have to go back and look to see if my recollection is correct. I suggest that you read the 10K and latest 10Q relating to the lawsuits and SEC inquiry. You're very good at that. Good luck!
Liz, Rocketjock has the only posts worth reading, IMO. I am sure you have done your own DD. GL!
SYN has not followed any pattern as to when earnings are released and their conference call, however, we are set up for a bullish call, IMO. Q2 2014 earnings were released on a Thursday with the call @ 8:30 am, while the Q1 2015 earnings released on a Monday and the call @ 4:30 PM. all adds to the intrigue. SYN cannot talk about the Trimesta trial results, but they can talk about their plans and progress. GLTA longs!
I do not think anyone said, "Halo should be at $100". What I have read is posters saying that HALO "WILL be at a $100" and the year 2019 is usually mentioned. IMO, that is hardly, "irrational". One could argue aggressive, but these are all guesstimates when you are referring to development stage companies. Frankly, I do not care what you do. I am an investor and not a trader and not much interested in the day to day fluctuations, but rather the tread. Short HALO as much as you look, since we cannot all be winners.
Perhaps, we can hear how HYQVIA sales are progressing in the US, Europe and ROW. Webcast can be access via Baxter's website.
Liz, since those images relate to testosterone treatment, why do you relate it to Trimesta? Thanks.
I found your 44 million number. First off, that 44 million people number is Alzheimer’s or a related dementia. The World Health Organization (WHO) says that 35.6 million people around the world are living with dementia. Trimesta trials are woman only. You assume 100% market penetration and everyone worldwide (from the US to Chad) takes the drug.
You're getting way, way ahead of yourself. I suggest that you wait for the data and then you can climb back on your soap box.